EuroBiotech: More Articles of Note

Acousia Therapeutics reeled in $10 million in series B funding. (NS Newsflash/CC BY 2.0)

> PhoreMost raised an £11 million ($15 million) series A round to expand its drug discovery activities. The Cambridge, U.K.-based startup is built upon a phenotypic screening platform. Statement

> CellCentric pulled in $26 million to fund clinical development of an inhibitor of p300 and CBP. The inhibition of the proteins is expected to cut expression of drivers of late-stage prostate cancer. Release 

> Polyphor raised CHF 165 million ($164 million) through an IPO in Switzerland. The IPO hit the upper end of the range and sold out its upsized overallotment. Polyphor is working on a phase 3 antibiotic and clinical-stage cancer asset. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Medicxi Ventures and RA Capital drove Xenikos to a $30 million series B. The Dutch biotech will spend the money on phase 3 trials of a treatment for graft versus host disease. Release 

> Acousia Therapeutics reeled in $10 million in series B funding. The money will support work on a pipeline of preclinical hearing loss prospects. Statement 

> Motif Bio filed to raise £10 million ($14 million). The money will support filings for approval of antibiotic iclaprim. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.